PMID- 37750416
OWN - NLM
STAT- MEDLINE
DCOM- 20230927
LR  - 20230927
IS  - 1096-9071 (Electronic)
IS  - 0146-6615 (Linking)
VI  - 95
IP  - 9
DP  - 2023 Sep
TI  - The binding profile of SARS-CoV-2 with human leukocyte antigen polymorphisms 
      reveals critical alleles involved in immune evasion.
PG  - e29113
LID - 10.1002/jmv.29113 [doi]
AB  - The COVID-19 pandemic, caused by the severe acute respiratory syndrome 
      coronavirus 2 (SARS-CoV-2), astonished the world and led to millions of deaths. 
      Due to viral new mutations and immune evasion, SARS-CoV-2 ranked first in 
      transmission and influence. The binding affinity of human leukocyte antigen (HLA) 
      polymorphisms to SARS-CoV-2 might be related to immune escape, but the mechanisms 
      remained unclear. In this study, we obtained the binding affinity of SARS-CoV-2 
      strains with different HLA proteins and identified 31 risk alleles. Subsequent 
      structural predictions identified 10 active binding sites in these HLA proteins 
      that may promote immune evasion. Particularly, we also found that the weak 
      binding ability with HLA class I polymorphisms could contribute to the immune 
      evasion of Omicron. These findings suggest important implications for preventing 
      the immune evasion of SARS-CoV-2 and providing new insights for the vaccine 
      design.
CI  - (c) 2023 Wiley Periodicals LLC.
FAU - Zhan, Yan
AU  - Zhan Y
AD  - Department of Clinical Pharmacology, Xiangya Hospital, Central South University, 
      Changsha, China.
AD  - Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, 
      Central South University, Changsha, China.
AD  - Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry 
      of Education, Beijing, China.
AD  - National Clinical Research Center for Geriatric Disorders, Changsha, China.
FAU - Ye, Ling
AU  - Ye L
AD  - Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South 
      University, Changsha, China.
FAU - Ouyang, Qianying
AU  - Ouyang Q
AD  - Department of Clinical Pharmacology, Xiangya Hospital, Central South University, 
      Changsha, China.
AD  - Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, 
      Central South University, Changsha, China.
AD  - Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry 
      of Education, Beijing, China.
AD  - National Clinical Research Center for Geriatric Disorders, Changsha, China.
FAU - Yin, Jiye
AU  - Yin J
AD  - Department of Clinical Pharmacology, Xiangya Hospital, Central South University, 
      Changsha, China.
AD  - Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, 
      Central South University, Changsha, China.
AD  - Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry 
      of Education, Beijing, China.
AD  - National Clinical Research Center for Geriatric Disorders, Changsha, China.
FAU - Cui, Jiajia
AU  - Cui J
AD  - Department of Geriatric Surgery, Xiangya Hospital, Central South University, 
      Changsha, China.
FAU - Liu, Ke
AU  - Liu K
AD  - Department of Clinical Pharmacology, Xiangya Hospital, Central South University, 
      Changsha, China.
AD  - Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, 
      Central South University, Changsha, China.
AD  - Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry 
      of Education, Beijing, China.
AD  - National Clinical Research Center for Geriatric Disorders, Changsha, China.
FAU - Guo, Chengxian
AU  - Guo C
AD  - Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South 
      University, Changsha, China.
FAU - Zhang, Haibo
AU  - Zhang H
AD  - Hangzhou Women's Hospital, Hangzhou, China.
FAU - Zhai, Jingbo
AU  - Zhai J
AD  - Key Laboratory of Zoonose Prevention and Control at Universities of Inner 
      Mongolia Autonomous Region, Medical College, Inner Mongolia Minzu University, 
      Tongliao, China.
FAU - Zheng, Chunfu
AU  - Zheng C
AUID- ORCID: 0000-0002-8797-1322
AD  - Department of Microbiology, Immunology and Infectious Diseases, Cumming School of 
      Medicine, University of Calgary, Calgary, Alberta, Canada.
FAU - Guo, Aoxiang
AU  - Guo A
AD  - Department of Pharmacy, The Seventh Affiliated Hospital, Sun Yat-sen University, 
      Shenzhen, China.
AD  - Shenzhen Key Laboratory of Chinese Medicine Active substance screening and 
      Translational Research, Shenzhen, China.
FAU - Sun, Bao
AU  - Sun B
AD  - Department of Pharmacy, The Second Xiangya Hospital, Central South University, 
      Changsha, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Med Virol
JT  - Journal of medical virology
JID - 7705876
RN  - 0 (HLA Antigens)
RN  - 0 (Histocompatibility Antigens Class II)
SB  - IM
MH  - Humans
MH  - *SARS-CoV-2/genetics
MH  - Immune Evasion
MH  - Alleles
MH  - Pandemics
MH  - *COVID-19
MH  - HLA Antigens
MH  - Histocompatibility Antigens Class II
OTO - NOTNLM
OT  - COVID-19
OT  - HLA genetics
OT  - SARS-CoV-2
OT  - immune evasion
OT  - viral infection
EDAT- 2023/09/26 13:42
MHDA- 2023/09/27 06:42
CRDT- 2023/09/26 06:57
PHST- 2023/08/26 00:00 [revised]
PHST- 2023/05/29 00:00 [received]
PHST- 2023/09/11 00:00 [accepted]
PHST- 2023/09/27 06:42 [medline]
PHST- 2023/09/26 13:42 [pubmed]
PHST- 2023/09/26 06:57 [entrez]
AID - 10.1002/jmv.29113 [doi]
PST - ppublish
SO  - J Med Virol. 2023 Sep;95(9):e29113. doi: 10.1002/jmv.29113.